Medindia LOGIN REGISTER
Medindia

Side effect(s) of Bictegravir, Emtricitabine, and Tenofovir Alafenamide


Review the side-effects of Bictegravir, Emtricitabine, and Tenofovir Alafenamide as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the instances these side-effects are mild and easily tolerable, however sometimes they can be more severe and can be detrimental.

If the side effects are not tolerable adjusting the dosage or switching to a different medication can help to manage or overcome side effects. If you have any doubts or questions, we recommend seeking advice from your doctor or pharmacist.

  Common:
Diarrhea, nausea, headache

  Gastrointestinal:
Loss of appetite, stomach discomfort

  Respiratory:
Difficulty in breathing

  Nervous system:
Inability to sleep, fatigue, abnormal dreams, dizziness

  Others:
Kidney impairment, decreased phosphorous levels in the blood, abnormal level of liver enzymes and alteration in neutrophil counts.

Other Precautions :

• Do not alter the dose or stop treatment without consulting the physician.
• Take exactly as directed and at the same time every day.
• Refill the medications before running short, as discontinuation even for short periods results in viral resistance which becomes difficult to treat.
• Medications should not be shared with other patients without physician approval even if they have a similar infection.

Drug Name : Bictegravir, Emtricitabine, and Tenofovir Alafenamide

Bictegravir, Emtricitabine, and Tenofovir Alafenamide generic Bictegravir, emtricitabine, and tenofovir alafenamide is a three-drug combination where bictegrair is an HIV-1 integrase strand transfer inhibitor, and emtricitabine and tenofovir alafenamide are HIV -1 nucleoside analog reverse transcriptase inhibitors prescribed to treat HIV infections in adults. The drug combination can be used in patients- • Who has not been previously treated with antiretroviral therapy • To replace current antiretroviral therapy for those who are virologically suppressed after taking antiretroviral regimen for at least three months; these patients must not have had any failed treatment nor any known substitutions associated with resistance to the individual components.


Advertisement